期刊
CURRENT RHEUMATOLOGY REPORTS
卷 15, 期 12, 页码 -出版社
SPRINGER
DOI: 10.1007/s11926-013-0380-9
关键词
Systemic lupus erythematosus; Quality of life; Patient-reported outcomes; Health-related quality of life; QoL; Clinical trials; Modifiers; Confounders
类别
资金
- GlaxoSmithKline/The Binding Site
- GlaxoSmithKline
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that has major implications for health-related quality of life (HRQoL). Improvements in the monitoring and management of SLE improves survival; however, improvement of HRQoL remains of paramount importance among these patients. Measurement of HRQoL has been recommended in clinical practice and research including drug development and testing in clinical trials. Both generic and disease specific instruments have been developed to ascertain HRQoL. In an increasingly global collaborative environment, the importance of assessing HRQoL across nations, acknowledgment of their confounders, and limitations of used instruments are critical. Here, we review selected major developments in the past 5 years highlighting: the importance of measuring HRQoL in SLE patients, the benefits and limitations of instruments that exist, and their application in research settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据